These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 16151771

  • 1. [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide.
    Stahl A, Meisetschläger G, Schottelius M, Bruus-Jensen K, Wolf I, Scheidhauer K, Schwaiger M.
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):45-52. PubMed ID: 16151771
    [Abstract] [Full Text] [Related]

  • 2. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ.
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [Abstract] [Full Text] [Related]

  • 3. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics.
    Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M.
    Eur J Nucl Med Mol Imaging; 2002 Jan; 29(1):28-38. PubMed ID: 11807604
    [Abstract] [Full Text] [Related]

  • 4. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
    Meisetschläger G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, Herz M, Wester HJ, Schwaiger M.
    J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
    [Abstract] [Full Text] [Related]

  • 5. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
    Helisch A, Förster GJ, Reber H, Buchholz HG, Arnold R, Göke B, Weber MM, Wiedenmann B, Pauwels S, Haus U, Bouterfa H, Bartenstein P.
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
    [Abstract] [Full Text] [Related]

  • 6. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ, Schottelius M, Scheidhauer K, Meisetschläger G, Herz M, Rau FC, Reubi JC, Schwaiger M.
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [Abstract] [Full Text] [Related]

  • 7. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ, Kooij PP, Bakker WH, Mäcke HR, Krenning EP.
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [Abstract] [Full Text] [Related]

  • 8. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M.
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [Abstract] [Full Text] [Related]

  • 9. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.
    Schottelius M, Rau F, Reubi JC, Schwaiger M, Wester HJ.
    Bioconjug Chem; 2005 Nov; 16(2):429-37. PubMed ID: 15769098
    [Abstract] [Full Text] [Related]

  • 10. Targeting somatostatin receptors: preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET.
    Leyton J, Iddon L, Perumal M, Indrevoll B, Glaser M, Robins E, George AJ, Cuthbertson A, Luthra SK, Aboagye EO.
    J Nucl Med; 2011 Sep; 52(9):1441-8. PubMed ID: 21852355
    [Abstract] [Full Text] [Related]

  • 11. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW.
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [Abstract] [Full Text] [Related]

  • 12. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC.
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [Abstract] [Full Text] [Related]

  • 13. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.
    Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, de Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S.
    Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):510-8. PubMed ID: 12582815
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, Mäcke HR.
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [Abstract] [Full Text] [Related]

  • 15. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, van Koetsveld PM, Srinivasan A, Krenning EP, Breeman WA.
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [Abstract] [Full Text] [Related]

  • 16. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
    Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, Mikolajczak R, Zorga P.
    J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
    [Abstract] [Full Text] [Related]

  • 17. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M, Scheidhauer K, Luyken C, Voth E, Hildebrandt G, Klug N, Schicha H.
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [Abstract] [Full Text] [Related]

  • 18. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
    Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sörensen J, Bergström M, Långström B.
    Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
    [Abstract] [Full Text] [Related]

  • 19. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ.
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [Abstract] [Full Text] [Related]

  • 20. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients.
    Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K, Bormans G, Deroose CM.
    Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3033-3046. PubMed ID: 32617641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.